These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36383903)

  • 41. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
    Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
    Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolving Landscape of Antibody Drug Conjugates in Lymphoma.
    Prakash R; Subbiah V; Iyer SP
    Cancer J; 2022 Nov-Dec 01; 28(6):479-487. PubMed ID: 36383911
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer.
    Weiten R; Bernhardt M; Niemann M; Kristiansen G; Grünwald V; Ritter M; Hölzel M; Eckstein M; Alajati A; Klümper N; Krausewitz P
    J Cell Mol Med; 2024 Jul; 28(14):e18572. PubMed ID: 39072867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current Therapy for Metastatic Urothelial Carcinoma.
    Nadal R; Clara JA; Valderrama BP; Bellmunt J
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer.
    Choi W; Lombardo K; Patel S; Epstein G; Feng M; Gabrielson A; Hahn NM; Hoffman-Censits J; McConkey D; Bivalacqua TJ; Matoso A; Kates M
    Eur Urol; 2022 Feb; 81(2):138-142. PubMed ID: 34736796
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Desai A; Abdayem P; Adjei AA; Planchard D
    Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
    Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
    Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review.
    Grant MJ; Stockhammer P; Austin MR; Nemeth Z; Petrylak DP
    Bladder Cancer; 2024; 10(1):9-23. PubMed ID: 38993528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
    Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
    Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
    Goldenberg DM; Sharkey RM
    MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
    Bouleftour W; Sargos P; Magne N
    Curr Oncol Rep; 2023 Mar; 25(3):181-188. PubMed ID: 36696077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new era in the treatment of urothelial carcinoma.
    Faltas B
    Urol Oncol; 2023 Oct; 41(10):395-397. PubMed ID: 37833099
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression].
    Wei T; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):211-220. PubMed ID: 38494768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
    Shafique MA; Haseeb A; Siddiq MA; Mussarat A; Rangwala HS; Mustafa MS
    Cancer Manag Res; 2023; 15():699-706. PubMed ID: 37485038
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
    Belluomini L; Avancini A; Sposito M; Milella M; Rossi A; Pilotto S
    Expert Opin Biol Ther; 2023; 23(11):1077-1087. PubMed ID: 36995069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
    Goldenberg DM; Sharkey RM
    Expert Opin Biol Ther; 2020 Aug; 20(8):871-885. PubMed ID: 32301634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates.
    Albarrán V; Rosero DI; Chamorro J; Pozas J; San Román M; Barrill AM; Alía V; Sotoca P; Guerrero P; Calvo JC; Orejana I; Pérez de Aguado P; Gajate P
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293515
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.
    Rigby M; Bennett G; Chen L; Mudd GE; Harrison H; Beswick PJ; Van Rietschoten K; Watcham SM; Scott HS; Brown AN; Park PU; Campbell C; Haines E; Lahdenranta J; Skynner MJ; Jeffrey P; Keen N; Lee K
    Mol Cancer Ther; 2022 Dec; 21(12):1747-1756. PubMed ID: 36112771
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sacituzumab govitecan: an antibody-drug conjugate.
    Sahota S; Vahdat LT
    Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.